Emerging research suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, appears to offer a notable development for obesity treatment. Early human investigations have indicated substantial reductions in body fat , potentially surpassing current obesity therapies . However , additional assessment is needed to completely und